Dr. Silverberg's research interests are in the investigation and management of disorders of bone and mineral metabolism. Her main area of interest is the clinical study of primary hyperparathyroidism, including non-traditional as well as classical manifestations of the disease, and options for medical therapy.
Dr. Silverberg's research interests are in the investigation and management of disorders of bone and mineral metabolism. Her primary research focus is in the investigation of primary hyperparathyroidism. She has been part of an ongoing NIH-funded longitudinal study of this disease since its inception in 1984, and continues to study various end-organ effects of this disorder, as well as the longitudinal effects of non-intervention and cure. Current areas of interest include the neuropsychiatric and cardiovascular manifestations of mild primary hyperparathyroidism, and longitudinal incidence of fracture in mild disease. Medical treatment options in primary hyperparathyroidism have also been a focus of research. Dr. Silverberg has performed studies of bisphosphonate therapy, SERM use and calcimimetic treatment of primary hyperparathyroidism. Currently, we are studying a calcimimetic agent in the treatment of the most severe forms of primary hyperparathyoidism: intractable primary hyperarathyroidism and parathyroid cancer. Finally, studies of the various biochemical forms of PTH secreted by the adenomatous parathyroid glands in patients with primary hyperparathyoidism, and hisotlogical and descriptive studies of patients with a new histologic type of primary hyperparathyoidism are also ongoing.
In addition to various studies of primary hyperparathyoidism, Dr. Silverberg is involved in several ongoing projects in other areas of mineral metabolism. She is heading an investigation of the effects of tamoxifen withdrawal on the skeletons of postmenopausal women with breast cancer. In addition, she is studying the effects of bariatric surgery on indices of mineral metabolism in the morbidly obese patient. Finally, she is a co-investigator on studies of PTH treatment in male osteoporosis and in conjunction with alendraonate in osteoporosis, and in the investigation of bone density in the Chinese population of New York City.
1. Rubin MR, Lee K, Silverberg SJ. (2003) Raloxifene lowers serum calcium and markers of bone turnover in primary hyperparathyroidism. J Clin Endocrinol Metab
2. Silverberg SJ. (2002) Non-classical target organs in primary hyperparathyroidism. J Bone Min Res
17 suppl 2:N117-25
3. Bilezikian JP, Potts JT, El-Hajj Fuleihan G, Kleerekoper M, Neer R, Peacock M, Rastad J, Silverberg SJ, Udelsman R, Wells SA. (2002) Summary statement from a workshop on asymptomatic primary hyperparathyroidism: a perspective for the 21st century. J Bone Min Res
17 suppl 2:N2-11
4. Rubin MR, Bilezikian JP, Silverberg SJ. (2002) Vascular stiffnes in increased in patients with primary hyperparathyroidism. J Bone Mineral Res
5. Silverberg SJ, Brown I, Bilezikian JP. (2002) Youthfulness as a criterion for surgery in primary hyperparathyroidism. Am J Med